BackAlbany Molecular Research Overview

Albany Molecular Research Long Term Debt

Albany Molecular Research's long-term debt is $200M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$195.59M
47.25% YoYΔ $-175.21M vs prior year quarter

Peer trimmed avg / median

Loading

Albany Molecular Research Long Term Debt History

Loading

Albany Molecular Research vs. peers: Long Term Debt Comparison

Loading

Albany Molecular Research Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Albany Molecular Research (AMRI) FAQ

The latest long-term debt for AMRI is $200M as of June 2017. That compares with $370M in the prior-year period — down 47.3% year over year. Investors often review this figure alongside Albany Molecular Research's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMRI's long-term debt moved from $370M to $200M — a 47.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Albany Molecular Research's operating scale or balance-sheet position.

A long-term debt figure of $200M for AMRI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMRI's long-term debt ($200M), review year-over-year change from $370M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.